Financial Performance - For the three months ended December 31, 2022, the company's revenue was HKD 16,913,000, a decrease of 16.5% compared to HKD 20,344,000 in the same period of 2021[4] - For the nine months ended December 31, 2022, the company's revenue was HKD 49,937,000, down 3.5% from HKD 51,699,000 in the same period of 2021[4] - The net profit attributable to the owners of the company for the nine months ended December 31, 2022, was HKD 4,522,000, a decrease of 12.3% from HKD 5,159,000 in the same period of 2021[4] - The company reported a profit attributable to owners of HKD 4,522,000 for the nine months ended December 31, 2022, down 12.4% from HKD 5,159,000 in 2021[25] - Profit for the nine months ended December 31, 2022, decreased by approximately HKD 700,000 to HKD 4,500,000, down from HKD 5,200,000 for the same period in 2021, mainly due to increased administrative and other operating expenses[34] Revenue Breakdown - Revenue from medical consumables for the nine months ended December 31, 2022, was HKD 38,990,000, an increase of 6.4% from HKD 36,653,000 in 2021[18] - Revenue from medical equipment for the nine months ended December 31, 2022, was HKD 8,037,000, a decrease of 32.4% compared to HKD 11,832,000 in 2021[18] - The group's revenue decreased by approximately 3.4% from HKD 51,700,000 for the nine months ended December 31, 2021, to HKD 49,900,000 for the nine months ended December 31, 2022[29] Profitability Metrics - The gross profit for the three months ended December 31, 2022, was HKD 8,628,000, representing a gross margin of 51.0%, compared to HKD 10,036,000 and a margin of 49.4% in the same period of 2021[4] - Gross profit for the nine months ended December 31, 2022, was approximately HKD 25,900,000, a decrease of about HKD 1,300,000 or 5.0% compared to HKD 27,200,000 for the same period in 2021[30] - The gross profit margin declined from approximately 52.7% for the nine months ended December 31, 2021, to approximately 51.8% for the nine months ended December 31, 2022, primarily due to fluctuations in overseas transportation costs[30] Expenses - Research and development expenses for the nine months ended December 31, 2022, were HKD 1,591,000, an increase of 32.9% from HKD 1,197,000 in 2021[21] - Administrative and other operating expenses increased by approximately HKD 700,000 or 3.5% to HKD 20,300,000 for the nine months ended December 31, 2022, compared to HKD 19,600,000 for the same period in 2021[31] - The cost of inventories recognized as an expense for the nine months ended December 31, 2022, was HKD 22,403,000, a decrease of 3.4% from HKD 23,185,000 in 2021[20] Dividends - The company did not declare an interim dividend for the nine months ended December 31, 2022, compared to no dividend declared for the same period in 2021[23] - The board resolved not to declare an interim dividend for the nine months ended December 31, 2022[35] Corporate Governance - The company has adopted the corporate governance code as per GEM listing rules and has complied with all provisions except for specific deviations[49] - The chairman and CEO roles are held by the same individual, which the board believes does not compromise independence or effectiveness[52] - All directors confirmed compliance with the trading standards and related codes of conduct during the nine months ended December 31, 2022[46] - There were no conflicts of interest reported by directors or employees in competing businesses as of December 31, 2022[48] Strategic Outlook - The company aims to diversify its product portfolio and enhance R&D capabilities to achieve business growth[27] - The company is optimistic about the healthcare industry outlook due to the increasing elderly population and rising health awareness among Hong Kong citizens[27] - The group plans to expand its product offerings and strengthen customer service to enhance its one-stop medical equipment solution services[27] - The company is seeking suitable investment opportunities to diversify its business and provide better returns to shareholders[27] Share Options - As of December 31, 2022, a total of 21,460,000 share options were available for issuance, with an exercise price of HKD 0.12 per share[43] - No share options were granted, exercised, forfeited, cancelled, or expired during the nine months ended December 31, 2022[44] - The maximum 40% of share options can be exercised after April 18, 2019, and 70% after April 18, 2020[44] Compliance and Audit - The audit committee, established on March 1, 2018, reviewed the unaudited consolidated financial statements for the nine months ended December 31, 2022, ensuring compliance with applicable accounting standards[53] - The company has not adopted any new accounting standards that have a significant impact on its financial performance for the current period[12] - The report was issued on February 10, 2023, with the executive director being the chairman and CEO, Ms. Huang Bi-Jun[55]
君百延集团(08372) - 2023 Q3 - 季度财报